Athenagen has acquired the assets of Osprey Pharmaceutical, including its lead drug candidate for Alzheimer's. Athenagen also nets a large library of analogs in the deal. Osprey's lead compound, GTS-21, is a selective alpha-7 nicotinic acetylcholine receptor agonist in Phase I. "GTS-21 is an excellent addition to our pipeline because it expands our nACh receptor-focused clinical portfolio with an additional therapeutic indication--Alzheimer's disease," said Athenagen CEO W. Scott Harkonen, M.D.
- see the release for more on the deal